Future scope: the next decade.
Forward views below are calibrated by confidence: high means trend is operational and trajectory clear; medium means direction is plausible but uncertain; low means the substrate exists but the regulatory infrastructure does not.
Future scope, 2026–2035.
Projections · with confidenceForward views below are calibrated by confidence: high means trend is operational and trajectory clear; medium means direction is plausible but politically or technically uncertain; low means the substrate exists but the regulatory and reimbursement infrastructure does not.
AI/ML-enabled trial designs become regulatory baseline.
Cohort enrichment / site selection standard from 2024+. Extending to adaptive design optimisation, real-time eligibility screening, AI-assisted SDV, safety-signal detection. FDA PCCP framework extends to trial AI ~2027. ICH E20 incorporates AI-adaptive. EU AI Act parallel obligation framework.
Synthetic control arms in pivotal trials accepted.
FDA rare-disease/oncology acceptance through 2025. EMA via Scientific Advice. Moving to broader ethical/feasibility-constrained use. FDA RWE Framework + ICH E11A + HMA-EMA Big Data Steering Group outputs shape trajectory. Single SCA failure-to-replicate would re-tighten.
In-silico evidence supplementing registration.
FDA Modernization Act 2.0 removed animal-testing mandate (headroom for alternatives including in-silico). CDRH accepted computational device modelling since 2016. Realistic: in-silico supplementing (not substituting) pivotal drug claims 2028–2033; full substitution device-side only.
Genomic-stratified · N-of-1 mainstream for ultra-rare.
Tumour-agnostic precedent (pembrolizumab MSI-H 2017) extends to biomarker-defined approvals. Bespoke Gene Therapy Consortium, FDA N-of-1 ASO draft 2021, EMA PRIME designation. Reimbursement barriers exceed regulatory ones.
Decentralised becomes default.
Hybrid trials (home nursing, telemedicine, direct-to-participant IMP) standard, not special. Phase-3-with-50-sites persists for complex imaging/surgical. Site-density question replaces yes/no. Cross-border data-transfer (GDPR, DPDP, LGPD) may divergence rather than converge.
Global CTR-equivalent harmonisation spreads.
EU CTR/CTIS template → ASEAN Joint Assessment, AVAREF extension, possible ACCESS Consortium expansion (FDA-MHRA-Health Canada-TGA-Singapore-Swissmedic). Project Orbis extends into CT-stage. Geopolitical decoupling could fracture consortium.
ICH E6(R4) horizon.
R1 1996 → R2 2016 → R3 2025 suggests R4 ~2032–2035. Will absorb Annex 2 (non-traditional designs), embed AI/ML in trial conduct, strengthen participant-as-stakeholder, integrate continuous submission, absorb SCA/RWE into main framework. R3 implementation gaps could defer R4 by 2–3 years.
India full ICH Regulatory Member.
NDCT 2019 track record, E6(R3) alignment via CDSCO inspection guidance 2026–2027, Q-series mature, PvPI expanding. WHO Listed Authority framework parallel-tracks maturity. Formal membership formalises bidirectional acceptance; India becomes regulatory-attractive, not just cost-attractive.
Continuous submission · living dossier.
Real-time data flow sponsor → regulator. AI-assisted review. Automated safety reporting. FDA PDUFA VII pilots. EMA DARWIN EU. Binding constraint: regulator IT infrastructure (historically optimistic by 2–3x).
Climate · sustainability metrics on the regulator agenda.
EMA 2023 reflection paper. MHRA signalled interest. Carbon footprint monitoring travel, disposable waste, IT infrastructure. Soft-regulation trajectory (expectation not statute). More visible EU than US politically.